Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

Gossage L, Madhusudan S.

Cancer Treat Rev. 2007 Oct;33(6):565-77. Epub 2007 Aug 17. Review.

PMID:
17707593
2.
3.

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC.

Cancer Res. 2003 Mar 15;63(6):1311-6.

4.

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB.

Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Review.

PMID:
18804893
5.

Excision repair cross complementing-group 1: gene expression and platinum resistance.

Altaha R, Liang X, Yu JJ, Reed E.

Int J Mol Med. 2004 Dec;14(6):959-70. Review.

PMID:
15547660
6.

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Jakobsen A.

Int J Gynecol Cancer. 2009 Jul;19(5):820-5. doi: 10.1111/IGC.0b013e3181a12e09.

PMID:
19574766
7.

[ERCC1 and lung cancer].

Planchard D, Olaussen KA, Soria JC.

Rev Mal Respir. 2010 Apr;27(4):387-94. doi: 10.1016/j.rmr.2010.03.003. Epub 2010 Mar 25. Review. French.

PMID:
20403548
8.

A review of excision repair cross-complementation group 1 in colorectal cancer.

Bohanes P, Labonte MJ, Lenz HJ.

Clin Colorectal Cancer. 2011 Sep;10(3):157-64. doi: 10.1016/j.clcc.2011.03.024. Epub 2011 Apr 28. Review.

PMID:
21855036
9.

Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.

Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ.

Biochem Biophys Res Commun. 2005 Feb 4;327(1):225-33.

PMID:
15629453
10.

Platinum resistance: the role of DNA repair pathways.

Martin LP, Hamilton TC, Schilder RJ.

Clin Cancer Res. 2008 Mar 1;14(5):1291-5. doi: 10.1158/1078-0432.CCR-07-2238. Review.

11.

Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.

Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, You HJ.

Cancer Res. 2004 Jul 15;64(14):4849-57. Erratum in: Cancer Res. 2004 Nov 15;64(22):8484.

12.

ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.

Metzger R, Bollschweiler E, Hölscher AH, Warnecke-Eberz U.

Future Oncol. 2010 Nov;6(11):1735-49. doi: 10.2217/fon.10.140. Review.

PMID:
21142660
13.

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.

Am J Clin Oncol. 2009 Feb;32(1):38-43. doi: 10.1097/COC.0b013e31817be58e.

PMID:
19194123
14.

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.

Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS, Lim HY.

Lung Cancer. 2008 Jan;59(1):95-104. Epub 2007 Sep 21.

PMID:
17889401
15.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

PMID:
18977553
16.

Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.

Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S.

Eur J Cancer. 2003 Jan;39(1):112-9.

PMID:
12504667
17.

Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.

Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, Miwa H.

Anticancer Res. 2008 Jul-Aug;28(4B):2087-92.

18.

The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.

Breen D, Barlési F.

Eur J Cardiothorac Surg. 2008 May;33(5):805-11. doi: 10.1016/j.ejcts.2008.01.067. Epub 2008 Mar 14. Review.

PMID:
18342529
19.

The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver.

Geva R, Shamai S, Brazowsky E, Paoulas M, Ben-Haim M, Johnstone E, Alex B, Shacham-Shmueli E.

Cancer Invest. 2015 Apr;33(4):89-97. doi: 10.3109/07357907.2014.998834. Epub 2015 Feb 27.

PMID:
25723812
20.

The role of glutathione in the regulation of nucleotide excision repair during oxidative stress.

Langie SA, Knaapen AM, Houben JM, van Kempen FC, de Hoon JP, Gottschalk RW, Godschalk RW, van Schooten FJ.

Toxicol Lett. 2007 Feb 5;168(3):302-9. Epub 2006 Nov 16.

PMID:
17207589

Supplemental Content

Support Center